Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM.
Here’s what investors need to know about the announcement.
Earnings
Ligand Pharmaceuticals beat estimated earnings by 67.21%, reporting an EPS of $1.02 versus an estimate of $0.61.
Revenue was down $33.22 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.78 which was followed by a 5.35% increase in the share price the next day.
Here’s a look at Ligand Pharmaceuticals’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | 0.64 | 0.89 | 1.19 | 0.43 |
| EPS Actual | 1.42 | 2.28 | 1.36 | 1.31 |
| Revenue Estimate | 25.73M | 34.04M | 46.64M | 38.28M |
| Revenue Actual | 26.37M | 43.98M | 50.38M | 66.09M |
To track all earnings releases for Ligand Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
